News
MXCT
0.8080
0.00%
0.0000
Weekly Report: what happened at MXCT last week (0126-0130)?
Weekly Report · 6d ago
Weekly Report: what happened at MXCT last week (0119-0123)?
Weekly Report · 01/26 09:16
Weekly Report: what happened at MXCT last week (0112-0116)?
Weekly Report · 01/19 09:18
MaxCyte Expects Core Revenue of Up to $29.6 Million for 2025
Reuters · 01/12 21:46
MaxCyte Reports Q4 Revenue Around $6.7M Vs $9.3M Est, Full-Year Revenue Near $30M Vs $35.41M Est
Benzinga · 01/12 13:18
MaxCyte sees Q4 core revenue between $6.6M and $6.7M
Seeking Alpha · 01/12 13:16
MaxCyte sees Q4 core revenue $6.6M-$6.7M, consensus $9.3M
TipRanks · 01/12 13:15
*MaxCyte Sees FY25 Core Rev $29.5M - $29.6M >MXCT
Dow Jones · 01/12 13:11
*MaxCyte Sees 4Q Core Rev $6.6M - $6.7M >MXCT
Dow Jones · 01/12 13:10
MAXCYTE INC <MXCT.O> Q4 REV VIEW $9.4 MLN -- LSEG IBES DATA
Reuters · 01/12 13:05
Weekly Report: what happened at MXCT last week (0105-0109)?
Weekly Report · 01/12 09:17
Weekly Report: what happened at MXCT last week (1229-0102)?
Weekly Report · 01/05 09:16
Weekly Report: what happened at MXCT last week (1222-1226)?
Weekly Report · 12/29/2025 09:16
Weekly Report: what happened at MXCT last week (1215-1219)?
Weekly Report · 12/22/2025 09:16
Weekly Report: what happened at MXCT last week (1208-1212)?
Weekly Report · 12/15/2025 09:18
Weekly Report: what happened at MXCT last week (1201-1205)?
Weekly Report · 12/08/2025 09:17
MaxCyte management to meet with Craig-Hallum
TipRanks · 12/02/2025 18:55
Weekly Report: what happened at MXCT last week (1124-1128)?
Weekly Report · 12/01/2025 09:16
Weekly Report: what happened at MXCT last week (1117-1121)?
Weekly Report · 11/24/2025 09:17
Weekly Report: what happened at MXCT last week (1110-1114)?
Weekly Report · 11/17/2025 09:17
More
Webull provides a variety of real-time MXCT stock news. You can receive the latest news about Maxcyte through multiple platforms. This information may help you make smarter investment decisions.
About MXCT
MaxCyte, Inc. is a commercial cell engineering company. The Company is focused on providing enabling platform technologies to advance the discovery, development and commercialization of cell therapeutics, including cell and gene therapies, and to support cell-based research and development. It has developed and commercialized its proprietary Flow Electroporation technology, which is used by biopharmaceutical companies in the complex engineering of a variety of cells. Its ExPERT platform is based on its Flow Electroporation technology, which has been designed to address this rapidly expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of cell-based medicines. The ExPERT family of products includes four instruments, which are known as the ATx, STx, GTx and VLx, as well as a portfolio of proprietary related disposables and consumables.